Oppenheimer analyst Andreas Argyrides lowered the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $62.00 (from $70.00) while ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE